Inhibiting SPHK2 decreases the growth of tumor cells, and expression of wild-type hTERT, but not the S1P-binding hTERT mutant, potentiates cancerous growth, which indicates that, under some circumstances, Sphk2 functions as a proto-oncogene (Panneer Selvam et al., 2015). This evidence concerns the gene SPHK2 and neoplasm.